Evidence map›Paper›PMID 35680377›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2022

A novel sulindac derivative protects against oxidative damage by a cyclooxygenase-independent mechanism.

Shailaja Kesaraju Allani, Ramanjaneyulu Rayala, Oscar Rivera, Howard M Prentice, Xi Chen, Veronica Ramírez-Alcántara, Joshua Canzoneri, Janet Menzie-Suderam, Xupei Huang, Constantin Georgescu and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Shailaja Kesaraju AllaniCenter for Molecular Biology and Biotechnology, Florida Atlantic University, United States hweissba@fau.edu.ORCID 0000-0002-1900-2933
Ramanjaneyulu RayalaFlorida Atlantic University, United States.
Oscar RiveraFlorida Atlantic University, United States.
Howard M PrenticeFlorida Atlantic University, United States.
Xi ChenAuburn University, United States.
Veronica Ramírez-AlcántaraUniversity of South Alabama, United States.
Joshua CanzoneriUniversity of South Alabama,, United States.
Janet Menzie-SuderamFlorida Atlantic University, United States.
Xupei HuangFlorida Atlantic University, United States.
Constantin GeorgescuOklahoma Medical Research Foundation, United States.
Jonathan D WrenOklahoma Medical Research Foundation, United States.
Gary A PiazzaAuburn University, United States.
Herbert WeissbachFlorida Atlantic University, United States hweissba@fau.edu.
Florida International University · US

Funding

Targeted DNA Methylation and Mitochondrial Heteroplasmy CoreP30AG050911 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI William Edmund Sonntag · 2015 to 2026
$13.9M
Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROSR01CA131378 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2008 to 2019
$5.2M
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer ChemopreventionR01CA155638 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2012 to 2017
$2.3M
Phosphodiesterase 10A, a novel target for lung cancer chemopreventionR01CA197147 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA131378NCI NIH HHS R01 CA155638NCI NIH HHS R01 CA197147NIA NIH HHS P30 AG050911
6 · The paper itself

Abstract

Oxidative damage is believed to play a major role in the etiology of many age-related diseases and the normal aging process. We previously reported that sulindac, a cyclooxygenase (COX) inhibitor and FDA approved anti-inflammatory drug, has chemoprotective activity in cells and intact organs by initiating a pharmacological preconditioning response, similar to ischemic preconditioning (IPC). The mechanism is independent of its COX inhibitory activity as suggested by studies on the protection of the heart against oxidative damage from ischemia/reperfusion and retinal pigmented endothelial (RPE) cells against chemical oxidative and UV damage

Indexed as

agingcardiac ischemiaCOX-1COX-2ischemia / reperfusion injuryoxidative injuryOxidative stressoxygen radicals

Identifiers

PMID35680377
PMCPMC9341458
OpenAlexW4282938258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.